Trump signs executive order to accelerate psychedelic drug research for mental health
Here's what it means for you.
This executive order could revolutionize mental health treatment protocols in the U.S., particularly for veterans.
What happened
Trump signed an executive order to fast-track psychedelic drug research.
The Context
- The order aims to ease restrictions on psychedelics like ibogaine.
- It targets treatments for mental health conditions such as PTSD, depression, and addiction.
- The move has been seen as a significant validation for the psychedelic industry.
Takeaway
The executive order could lead to increased investment and research in psychedelic therapies.
Medical reporting with scientific depth and public service tone.
"NPR is a nonprofit media organization offering thoughtful, in-depth journalism and storytelling, often with a liberal or progressive slant."
— A47 Editor
Trump's order is a milestone for proponents of using psychedelics as medicine
President Donald Trump has signed an executive order aimed at accelerating the research and approval of psychedelic substances, including psilocybin and ibogaine, for treating mental health conditions such as depression, PTSD, and addiction. This ini...
Public health news, medical research, and wellness coverage.
"NBC News is a mainstream outlet known for comprehensive national and international news coverage with a centrist to slightly left-leaning editorial tone."
— A47 Editor
Trump signs order to speed up review of psychedelic drugs for mental health treatment
President Trump signed an executive order on April 18, 2026, aimed at expediting the review process for psychedelic drugs, including ibogaine, which are currently classified under the federal government's most restrictive category. This order is inte...
Conservative-leaning coverage of current events.
"Fox News is a highly influential conservative news outlet known for right-leaning political commentary and coverage."
— A47 Editor
Joe Rogan reveals text to Trump that helped expedite federal review of psychedelics
President Donald Trump signed an executive order on April 18, 2026, to expedite the federal review of psychedelic drugs, including ibogaine, following a text exchange with podcaster Joe Rogan. This initiative aims to enhance research into treatments ...
Business, investment, entrepreneurship, leadership, and innovation.
"Forbes is known for its coverage of business leaders, market trends, and entrepreneurial ventures with a pro-business editorial stance."
— A47 Editor
Psychedelic Stocks Surge After Trump Signs Order Fast-Tracking Drug Research
The Trump administration has signed an order to expedite the review process for psychedelic substances, a move that has been positively received by analysts who view it as a significant endorsement for the industry. This initiative aims to facilitate...